Open AccessArtemisinin and multidrug-resistant Plasmodium falciparum – a threat for malaria control and elimination
Author(s) -
Mehul Dhorda,
Chanaki Amaratunga,
Arjen M. Dondorp
Publication year - 2021
Publication title -
current opinion in infectious diseases/current opinion in infectious diseases, with evaluated medline
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.68
H-Index - 103
eISSN - 1080-7861
pISSN - 0951-7375
DOI - 10.1097/qco.0000000000000766
Subject(s) - artemisinin , malaria , medicine , drug resistance , plasmodium falciparum , multiple drug resistance , virology , biology , immunology , microbiology and biotechnology
Artemisinin-based combination therapies (ACTs) are globally the first-line treatment for uncomplicated falciparum malaria and new compounds will not be available within the next few years. Artemisinin-resistant Plasmodium falciparum emerged over a decade ago in the Greater Mekong Subregion (GMS) and, compounded by ACT partner drug resistance, has caused significant ACT treatment failure. This review provides an update on the epidemiology, and mechanisms of artemisinin resistance and approaches to counter multidrug-resistant falciparum malaria.